GO
| HSI1 | 25,116.85 | 0.00 | -- |
| HSCEI1 | 8,340.83 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2026-08-16 19:13:18 GENSCRIPT BIO (01548.HK) announced its interim results for the six months ended June 2026. On a non-IFRS basis, revenue rose 27.3% YoY to USD404 million. Loss narrowed to USD129 million from a loss of USD182 million in the corresponding period last year. LPS was USD5.92 cents. No dividend was declared. During the period, gross profit increased 48% to USD207 million. Adjusted net profit grew 203.3% to USD62.5 million. Excluding Legend accounted for under the equity method, the core business recorded net profit of USD25.6 million, up 116.7%.(d)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |